Latest Investment News

Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.

Immutep Limited reported a widened loss of A$61.4 million for FY2025, driven by increased R&D and clinical trial expenses, while progressing its lead immunotherapy candidate into a pivotal Phase III lung cancer trial. The company maintains a robust cash position supporting operations through 2026.

EPX Limited reported a 17.2% increase in revenue to $15.27 million for FY2025, alongside an 18.7% rise in net loss to $5.75 million. The company expanded its energy management portfolio with the acquisition of UK-based Coda Cloud Limited and raised $5 million in equity to fuel growth.

3P Learning reported a 30% rise in underlying EBITDA to $15.5 million for FY25, alongside a return to statutory profitability and a key acquisition to strengthen its literacy offerings.

Hubify Limited reports a significant turnaround in FY25 with positive EBITDA and a robust cash position, despite a strategic revenue decline. The company’s focus on recurring managed services and cybersecurity positions it well for future growth.

Careteq Limited reported a dramatic reduction in its FY25 loss to just $72,204, down from $2.67 million the prior year, while facing a significant $3.6 million dispute with the Australian Taxation Office over R&D tax claims.

Pure Foods Tasmania has executed a decisive operational and financial turnaround, cutting costs and strengthening its balance sheet, while targeting breakeven by mid-2026 with ambitious growth plans.

Regal Asian Investments has commenced on-market share purchases to satisfy its Dividend Reinvestment Plan, pricing shares at or below its recent net tangible asset value of $2.54. This move signals a strategic approach to capital management amid evolving portfolio stewardship.

Mayne Pharma Group Limited reported a robust FY25 with a 5% revenue increase to A$408.1 million and a 105% surge in underlying EBITDA, driven by strong growth in Women’s Health and strategic acquisitions in Dermatology.

Mayne Pharma reported a robust 5% revenue increase to $408.1 million and more than doubled its underlying EBITDA to $47 million in FY25, driven by strong Women’s Health sales and strategic acquisitions in Dermatology.

PointsBet reports a 6% revenue increase and returns to normalised EBITDA profitability in FY25, while the board unanimously backs MIXI Australia’s all-cash $1.25 per share takeover offer, urging shareholders to reject a rival hostile bid.

Mayne Pharma reported a 5% revenue increase to $408.1 million for FY25 but posted a net loss of $93.8 million, narrowing from the prior year. The company’s planned acquisition by Cosette Pharmaceuticals faces legal hurdles, delaying completion.